粪便微生物移植与免疫检查点抑制剂联合治疗实体瘤的应用研究进展

Advances on the Application of Fecal Microbial Transplantation in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors

免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)治疗作为免疫治疗的一项重大临床进步,已被证明可以提高多种类型癌症患者的总生存期。肠道菌群及其代谢产物在调节局部和全身免疫反应中发挥重要功能,因此研究肠道菌群对ICIs治疗的影响显得尤为重要。粪便微生物移植(fecal microbial transplantation,FMT)是从健康人捐献的粪便中分离出粪便菌群,以细菌液或胶囊的形式灌注或者口服移植到患者的肠道中,以取代患者体内不健康的肠道菌群。越来越多的证据证明,FMT在肿瘤治疗领域特别是提高肿瘤免疫治疗效果方面取得了许多进展。全文主要综述FMT与ICIs在治疗实体瘤中的研究进展,并对未来的研究方向进行了展望。

Immune checkpoint inhibitors(ICIs)therapy,a major clinical advancement in immunotherapy,can improve the overall survival of patients with many types of cancer.Gut flora and its metabolites are involved in regulating local and systemic immune responses,and it would be helpful to study the impact of gut flora on the treatment of ICIs.Fecal microbial transplantation(FMT)is the process of isolating fecal flora from donated feces of healthy individuals and transplanting them into the patient's intestine by infusion or orally in the form of bacterial fluid or capsules to replace unhealthy intestinal flora in the patient.In recent years,there is increasing evidence that FMT has made progress in the field of oncology treatment,especially by improving the effectiveness of tumor immunotherapy.This review discusses the research progress of FMT combined with ICIs in the treatment of solid tumors and provides an outlook on future research directions.